Related Experiment Video
Updated: Sep 12, 2026
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
Evolution of proton pump inhibitor research in reflux esophagitis: a Web of Science-based global bibliometric
Yongsen Wang1,2, Rui Wang3, Tian Wang4
1Gastroenterology Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Background:
Reflux esophagitis remains a prevalent acid-related disorder with an increasing global burden, yet the growing challenges of refractory disease and the transition toward newer acid-suppressing agents highlight critical knowledge gaps. This study aimed to analyze the global research trends and identify emerging hotspots in proton pump inhibitors (PPIs) treatment for reflux esophagitis through a Web of Science-based bibliometric analysis [1990-2026].
Methods:
A systematic search was conducted in the Web of Science Core Collection (WoSCC) on June 18, 2026, using MeSH-derived terms. Only English-language original research articles were included. Two independent researchers manually screened all records for relevance. The analysis was performed using VOSviewer, CiteSpace, and the "bibliometrix" package of R.
Results:
A total of 338 articles were included. Publications showed an overall upward trend with an annual growth rate of 2%. Japan emerged as the leading country (111 publications), followed by the United States [59] and China [38]. The American Journal of Gastroenterology and the Journal of Gastroenterology were the most influential journals. Keyword co-occurrence analysis identified five major research clusters spanning clinical assessment, pathophysiological mechanisms, disease classification, pharmacological evaluation, and comparative clinical trials, with research evolving from early PPI efficacy studies [1991-2005] to disease mechanisms [2005-2015] and to patient-centered outcomes [2015-2026].
Conclusions:
Three distinct research phases were identified in PPI treatment for reflux esophagitis. Current research insufficiently addresses the long-term impact of PPIs on gut microbiome and the comparative effectiveness of emerging potassium-competitive acid blockers (P-CABs). Future research should prioritize pharmacogenetic optimization, real-world evidence generation for novel therapeutic agents, and enhanced international collaboration.
Related Concept Videos
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:21Stomach pH Regulation
The acid-secreting gastric mucosal epithelial cells (parietal cells) lining the stomach lumen maintain the low pH in the lumen. Numerous ion transporters and channels on these parietal...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:27ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and are...